Oral Abstract Session:
125. Antiretroviral Therapy: New Drugs and Treatment Outcomes
Friday, October 9, 2015: 10:30 AM-12:00 PM
Room: 25--ABC

Learning Objectives:

-

Tracks: Adult ID, Epidemiology and Infection Control, HIV-STD-TB, Investigative ID

Moderators:  Karen Tashima, MD, FIDSA, Alpert Medical School of Brown University and Roberto Arduino, MD, The University of Texas Health Science Center at Houston

Presentations:
10:30 AM
725
Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1 Infected Virologically Suppressed Adults
Melanie Thompson, MD ; Javier Morales-Ramirez, MD ; Cheryl Mcdonald, MD ; Anita Rachlis, MD ; Christian Hoffmann, MD ; Adriano Lazzarin, MD ; Gordon Crofoot, MD ; Andrew Plummer, PhD ; Ya-Pei Liu, PhD ; Andrew Cheng, MD PhD ; Scott Mccallister, MD
10:45 AM
726
Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treatment-Experienced HIV-1 infected Adults (NCT01968551)
Gregory Huhn, MD, MPHTM ; Pablo Tebas, MD, FIDSA ; Joel Gallant, MD, MPH, FIDSA ; Timothy Wilkin, MD/MPH, FIDSA ; Andrew Cheng, MD PhD ; Mingjin Yan, PhD ; Christian Callebaut, PhD ; Marshall Fordyce, MD ; Moupali Das, MD, MPH ; Scott Mccallister, MD
11:00 AM
727
Lack of Drug Interactions between Boosted and Unboosted Tenofovir Alafenamide-based Antiretroviral Single Tablet Regimens (Emtricitabine/Rilpivirine/Tenofovir Alafenamide and Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) and the anti-HCV Single Tablet Regimen Ledipasvir/Sofosbuvir
Joseph Custodio, PhD ; Eileen Doyle, PharmD ; Phillip S. Pang, MD, PhD ; Moupali Das, MD, MPH ; Huyen Cao, MD ; Grace Ma, PhD ; Anita Mathias, PhD ; Julia Zack, PharmD
11:15 AM
728
2014 Affordable Care Act Enrollment of AIDS Drug Assistance Program Clients and Associated HIV Outcomes
Kathleen Mcmanus, MD, MS ; Anne Rhodes, PhD ; Lauren Yerkes, MPH ; Steven Bailey, LCSW ; Rebecca Dillingham, MD, MPH
11:30 AM
729
HIV Viral Control and Comorbidity Control are Not Highly Correlated at the Level of the HIV Clinic
Michael Ohl, MD, MSPH ; Kelly Richardson, PhD ; Victoria Parker, DBA ; Holly Swan, PhD ; Donald Mcinnes, ScD ; Vera Yakovchenko, MPH ; Amanda Midboe, PhD ; Barbara Bokhour, PhD
11:45 AM
730
Safety of optimized antiretroviral therapy during allogeneic matched and haploidentical bone marrow transplant in HIV+ individuals
Ayla Cash, MPH ; Adam Capoferri, B.Sc. ; Daniel Xu, B.Sc. ; Holly Mchugh, ScM ; Oliver Laeyendecker, PhD ; Sarah Sakoian, RN ; Lori Tony, RN ; Cynthia Bullen, PhD ; Christopher Pohlmeyer, B.Sc. ; Paul Pham, PharmD, BCPS ; Jun Lai, B.A. ; Joel Gallant, MD, MPH, FIDSA ; Robert Siliciano, MD, PhD ; Charles Flexner, MD ; Keith Pratz, MD ; Mark Levis, MD ; Richard Jones, MD ; Yvette Kasamon, MD ; Richard Ambinder, MD, PhD ; Christine Durand, MD

CME Credits:

ACPE Credits:

ACPE Number:


See more of: Oral Abstract Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.